Auto-antibodies to type I IFNs can underlie adverse reactions to yellow fever live attenuated vaccine

P Bastard, E Michailidis, HH Hoffmann… - Journal of Experimental …, 2021 - rupress.org
P Bastard, E Michailidis, HH Hoffmann, M Chbihi, T Le Voyer, J Rosain, Q Philippot…
Journal of Experimental Medicine, 2021rupress.org
Yellow fever virus (YFV) live attenuated vaccine can, in rare cases, cause life-threatening
disease, typically in patients with no previous history of severe viral illness. Autosomal
recessive (AR) complete IFNAR1 deficiency was reported in one 12-yr-old patient. Here, we
studied seven other previously healthy patients aged 13 to 80 yr with unexplained life-
threatening YFV vaccine–associated disease. One 13-yr-old patient had AR complete
IFNAR2 deficiency. Three other patients vaccinated at the ages of 47, 57, and 64 yr had high …
Yellow fever virus (YFV) live attenuated vaccine can, in rare cases, cause life-threatening disease, typically in patients with no previous history of severe viral illness. Autosomal recessive (AR) complete IFNAR1 deficiency was reported in one 12-yr-old patient. Here, we studied seven other previously healthy patients aged 13 to 80 yr with unexplained life-threatening YFV vaccine–associated disease. One 13-yr-old patient had AR complete IFNAR2 deficiency. Three other patients vaccinated at the ages of 47, 57, and 64 yr had high titers of circulating auto-Abs against at least 14 of the 17 individual type I IFNs. These antibodies were recently shown to underlie at least 10% of cases of life-threatening COVID-19 pneumonia. The auto-Abs were neutralizing in vitro, blocking the protective effect of IFN-α2 against YFV vaccine strains. AR IFNAR1 or IFNAR2 deficiency and neutralizing auto-Abs against type I IFNs thus accounted for more than half the cases of life-threatening YFV vaccine-associated disease studied here. Previously healthy subjects could be tested for both predispositions before anti-YFV vaccination.
rupress.org